NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ:SYRS). Such investors are ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sunisa Lee, the defending Olympic all-around gold medalist and uneven bars bronze medalist, may attempt a new skill at the 2024 Paris Games. The new element in her uneven bars routine is a release ...

A downtrend has been apparent in Syros Pharmaceuticals, Inc. (SYRS) lately with too much selling pressure. The stock has declined 70.6% over the past four weeks. However, given the fact that it is ...

Syros Pharmaceuticals’ SYRS shares plunged 61.7% on Aug 13, after the company discontinued enrollment in the mid-stage acute myeloid leukemia (AML) study of its investigational candidate ...

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a ...